Abstracts tagged "Myositis and randomized trials"

Abstract Number: 8L • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis
Anthony A. Amato¹, Umesh Badrising², Olivier Benveniste³, Merrilee Needham⁴, Hector Chinoy⁵, Min Wu⁶, Barbara Koumaras⁶, Ana de Vera⁷, Dimitris A. Papanicolaou⁶ and Michael G. Hanna⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Department of Neurology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Pitié-Salpêtrière Hospital, Pierre et Marie-Curie University, Paris, France, ⁴Fiona Stanley Hospital, IIID Murdoch University and Notre Dame University, Perth, Australia, ⁵Centre for Musculoskeletal Research, NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom

Background/Purpose: Bimagrumab (BYM338) is a novel fully human monoclonal antibody that binds competitively to activin type II receptors with greater affinity than natural inhibitory ligands…